Press Releases August 3, 2026 08:00 AM

electroCore to Participate in Upcoming Investor Conferences

electroCore management to present at upcoming virtual and in-person investor conferences

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
ECOR

electroCore, Inc., a bioelectronic medicine company, announced its participation in the Needham Virtual MedTech and Diagnostics Conference and the Canaccord Genuity Growth Conference in August 2026, with management presenting and holding one-on-one investor meetings.

electroCore to Participate in Upcoming Investor Conferences
ECOR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • electroCore to present at two major investor conferences in August 2026.
  • Company focuses on non-invasive bioelectronic technology products for chronic pain and wellness.
  • Presentations and meetings aim to engage investors and increase visibility.

ROCKAWAY, N.J., Aug. 03, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the following investor conferences:

  • Needham 11th Annual Virtual MedTech and Diagnostics Conference, taking place virtually on Tuesday, August 11, 2026. Management will host one-on-one meetings virtually.
  • Canaccord Genuity 46th Annual Growth Conference, taking place in Boston, Massachusetts, on Tuesday, August 11, and Wednesday, August 12, 2026, at the InterContinental Boston. Management will present on Tuesday, August 11, at 4:30 p.m. ET and will host one-on-one meetings on Wednesday, August 12.

Investors who wish to request a meeting should contact their sales representative at the sponsoring firms or reach out to electroCore Investor Relations at [email protected].

About electroCore, Inc.
electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore® non-invasive vagus nerve stimulation (nVNS) and Quell® neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga™ and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.

For more information, visit www.electrocore.com.

Contact:
ECOR Investor Relations
(973) 302-9253
[email protected]


Risks

  • Investor interest may not translate into increased stock value if future growth is uncertain.
  • Dependence on market acceptance of bioelectronic medicine and wellness products.
  • Potential regulatory or competitive challenges in the medtech sector impacting business prospects.

More from Press Releases

Golar LNG announces a new $600 million senior secured Revolving Credit Facility Aug 3, 2026 Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance Aug 3, 2026 Horse Racing’s Biggest Events Unite in Landmark New “Thoroughbred Championship Series” Aug 3, 2026 Amaze Holdings Announces Leadership Transition Aug 3, 2026 SEALSQ Highlights Growing Importance of Hardware-Based Crypto-Agility as AI Accelerates Cryptanalysis Aug 3, 2026